Technology ID
TAB-3585
A Novel High-Throughput Assay for Identifying Zike Virus NS2B-NS3 Protease Inhibitors
E-Numbers
E-043-2017-0
Lead Inventor
Li, Hongmin (Health Research Incorporated)
Co-Inventors
Xia, Menghang (NCATS)
Huang, Ruili (NCATS)
Kramer, Laura (Health Research Incorporated)
Li, Zhong (Health Research Incorporated)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Infectious Disease
Research Products
Research Equipment
Lead IC
NCATS
ICs
NCATS
This invention includes a novel high-throughput assay to identify orthosteric inhibitors blocking the Zika virus NS2B-NS3 protease. Pathogenic flaviviruses, including Zika, require the NS2B-NS3 protease for viral replication. There is currently an unmet need for specific antiviral therapeutics against the Zika virus. Preliminary screening using the NCGC Pharmaceutical Collection library identified a group of drugs including temoporfin, erythrosin B, niclosamide, and nitazoxanide that can significantly inhibit the interactions between NS2B and NS3.
Commercial Applications
The assay included in this invention can be used to identify novel compounds that inhibit the NS2B-NS3 interaction.
Competitive Advantages
The described assay is the first high-throughput method to aid in the identification of a flavivirus NS2B-NS3 protease inhibitor.
Licensing Contact: